Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

24,245 signal articles · 86 in last 24h · 115,172 total before filter · latest 1h ago
86last 24h
1824last 7d
297● bullish (7d)
170● bearish (7d)
205publishers
AllMacro324Earnings871M&A106Regulatory24Product17Analyst25
✕ clear all filtersticker: ^GSPCSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
3 Reasons to Avoid BEN and 1 Stock to Buy Instead
StockStory22d agobullish
3 Reasons to Avoid BEN and 1 Stock to Buy Instead

Franklin Resources has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.8%. The stock now trades at $32.49, marking a 28.4% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

The EM ETF Built on Demographics, Not Tech Hype
etf.com22d agoneutral
The EM ETF Built on Demographics, Not Tech Hype

<p>That EM ETF you added to your portfolio years ago for diversification purposes may actually just be delivering more of what you’re already getting an overabundance of via domestic equities: tech. The RISE ETF offers a genuinely differentiated approach to EM investing that won’t deliver 40% tech sector exposure (it’s just 5% of the fund). Tune into this episode of <em>Behind the Ticker</em> to learn more. </p>

3 Reasons to Avoid DHT and 1 Stock to Buy Instead
StockStory22d agobullish
3 Reasons to Avoid DHT and 1 Stock to Buy Instead

DHT Holdings currently trades at $18.16 and has been a dream stock for shareholders. It’s returned 214% since July 2021, more than tripling the S&P 500’s 70.1% gain. The company has also beaten the index over the past six months as its stock price is up 31.4% thanks to its solid quarterly results.

3 Reasons MD is Risky and 1 Stock to Buy Instead
StockStory22d agobullish
3 Reasons MD is Risky and 1 Stock to Buy Instead

Pediatrix Medical Group has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.3%. The stock now trades at $25.83, marking a 19.9% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

1 S&P 500 Stock on Our Buy List and 2 Facing Challenges
StockStory22d agobullish
1 S&P 500 Stock on Our Buy List and 2 Facing Challenges

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Time to Jump In? Raymond James Is Bullish on These 2 Stocks
TipRanks23d agobullish
Time to Jump In? Raymond James Is Bullish on These 2 Stocks

Geopolitics have been making headlines again – war in the Middle East and uncertainty in the price of oil are stirring up the headwinds. Yet, the S&P 500 has remained resilient, supported by strong corporate earnings. During the first-quarter earnings season, tech companies helped drive overall year-over-year earnings growth of 28.6%, the strongest quarter since late 2021, and expectations remain high for the second quarter, with FactSet forecasting earnings growth above 20% for a second consecu